Mrs. Maria José García | Gastrointestinal Pharmacology | Best Researcher Award

Hospital Universitario Marqués de Valdecilla | Spain

Mrs. María José García is a distinguished gastroenterologist renowned for her pioneering contributions to the understanding and treatment of inflammatory bowel diseases (IBD) and related gastrointestinal disorders. Currently serving as FEA Digestivo at the Hospital de Laredo, she has earned recognition as an accomplished clinician, educator, and researcher, with a strong commitment to advancing evidence-based gastroenterology. Her academic journey began with a degree in Medicine and Surgery from the University of Salamanca, followed by doctoral training in Biomedicine and Health Sciences at the University of Cantabria. This academic foundation, combined with her dedication to clinical excellence, has positioned her among the most respected figures in the field of digestive health.Her professional path includes prestigious international fellowships at Saint-Antoine Hospital in Paris and the Academic Medical Center in Amsterdam, where she deepened her expertise in the diagnosis and management of complex gastrointestinal conditions. These experiences allowed her to collaborate with leading European experts and integrate cutting-edge therapeutic innovations into clinical practice. Mrs. García’s research has been instrumental in shaping modern therapeutic approaches for IBD, particularly in evaluating biologic agents, third-line rescue therapies, and the withdrawal of antitumour necrosis factor treatments in patients achieving remission.Throughout her career, she has authored and co-authored numerous high-impact scientific articles published in prestigious journals such as Gut, Alimentary Pharmacology & Therapeutics, Therapeutic Advances in Gastroenterology, and Digestive and Liver Disease. Her most influential works have examined topics including inflammatory pouch disorders, safety and efficacy of advanced biologic therapies, and comparative analyses between novel treatment modalities for Crohn’s disease and ulcerative colitis. These studies have contributed valuable insights into optimizing patient care and personalizing treatment strategies across diverse clinical settings.Mrs. García’s scientific impact is underscored by an impressive record of 656 citations from 602 documents, 48 published papers, and an h-index of 14, reflecting both the quality and reach of her research. Her work continues to influence the global gastroenterology community, inspiring ongoing innovation and collaboration. Beyond research, she actively engages in knowledge dissemination through national and international conferences, promoting the integration of clinical practice with scientific discovery. Mrs. María José García stands as a model of excellence in gastroenterology—uniting clinical skill, academic rigor, and compassionate care to enhance the lives of patients worldwide.

Profile: Scopus

Featured Publications

Authors. (2025). Persistence, effectiveness, and safety of upadacitinib in Crohn’s disease and ulcerative colitis in real life: Results from a Spanish nationwide study (Ureal Study). American Journal of Gastroenterology.

Authors. (2025). Withdrawal of antitumour necrosis factor in inflammatory bowel disease patients in remission: A randomised placebo-controlled clinical trial of GETECCU. Gut.

Authors. (2025). Types, behaviour and therapeutic requirements of inflammatory pouch disorders: Results from the RESERVO study of GETECCU. Digestive and Liver Disease.

Authors. (2025). Exploration of fecal microbiota in newly diagnosed patients with inflammatory bowel disease using shotgun metagenomics. Frontiers in Cellular and Infection Microbiology.